Comparing Harvard Bioscience (HBIO) & Its Competitors
Harvard Bioscience (NASDAQ: HBIO) is one of 87 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Harvard Bioscience to similar companies based on the strength of its valuation, earnings, analyst recommendations, risk, profitability, institutional ownership and dividends.
Institutional & Insider Ownership
60.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 9.8% of Harvard Bioscience shares are held by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings for Harvard Bioscience and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Harvard Bioscience Competitors||267||1867||3359||108||2.59|
Harvard Bioscience presently has a consensus target price of $5.75, indicating a potential upside of 66.67%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 11.97%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, equities analysts plainly believe Harvard Bioscience is more favorable than its peers.
Risk & Volatility
Harvard Bioscience has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Harvard Bioscience’s peers have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.
Earnings and Valuation
This table compares Harvard Bioscience and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Harvard Bioscience||$104.52 million||-$4.30 million||-38.33|
|Harvard Bioscience Competitors||$2.13 billion||$221.25 million||2.04|
Harvard Bioscience’s peers have higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Harvard Bioscience and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Harvard Bioscience Competitors||-299.57%||-36.17%||-12.71%|
Harvard Bioscience beats its peers on 8 of the 13 factors compared.
About Harvard Bioscience
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.